title: [Demyelinating disease and vaccination of the human papillomavirus].
abstract: BACKGROUND
  Primary prevention by prophylactic vaccination against the major cause of cervical cancer, the carcinogenic human papillomavirus (HPV) types 16 and 18, is now available worldwide. Postlicensure adverse neurological effects have been described. The studies realized after the license are descriptive and limited by the difficulty to obtain the information, despite most of the statistical indexes show that the adverse effects by the vaccine of the HPV are not upper compared with other vaccines, the substimation must be considered.
  
  
  METHODS
  We describe the cases of four young women that developed demyelinating disease after the vaccination of the HPV, with a rank of time between the administration of the dose and the development of the clinical of seven days to a month, with similar symptoms with the successive doses. We have described six episodes coinciding after the vaccination.
  
  
  CONCLUSIONS
  Have been described seizures, autoimmune disorders such as Guillain-Barre syndrome, transverse myelitis, or motor neuron disease, probably adverse effects following immunization by HPV vaccine. So we suggest that vaccine may trigger an immunological mechanism leading to demyelinating events, perhaps in predisposed young.
authors.affiliation: Servicio de Neurología, Hospital General de Ciudad Real, Ciudad Real, España. mape1012001@hotmail.com
authors.forename: M Josefa
authors.initials: MJ
authors.lastname: Álvarez-Soria
authors.forename: Amalia
authors.initials: A
authors.lastname: Hernández-González
authors.forename: Sira
authors.initials: S
authors.lastname: Carrasco-García de León
authors.forename: M Ángeles
authors.initials: MÁ
authors.lastname: del Real-Francia
authors.forename: M José
authors.initials: MJ
authors.lastname: Gallardo-Alcañiz
authors.forename: José L
authors.initials: JL
authors.lastname: López-Gómez
mesh_terms: D000293:Adolescent; D000328:Adult; D001921:Brain / Q000473:pathology; D003711:Demyelinating Diseases / Q000209:etiology* / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D030361:Papillomavirus Infections / Q000150:complications / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000009:adverse effects* / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000209:etiology / Q000517:prevention & control / Q000821:virology
chemical_list: D053918:Papillomavirus Vaccines